MEDIA INQUIRIES
Becky Levine (919) 667-8711
blevine@omeza.com
Bernadette Cupit (908) 334-4554
bcupit@omeza.com
Positive Results from Diabetic Foot Ulcer Clinical Trial Show Dramatic Healing Rate within 12 Weeks or Less Using Novel OMEZA® Platform and Offloading
Sarasota, Fla., March 14, 2024 — Omeza®, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, today presented positive interim data from a diabetic foot ulcer (DFU) …
OCM™ Wound Platform Demonstrates Antibacterial Activity in Porcine Wound Model, Significantly Reducing Methicillin-Resistant Staphylococcus Aureus (MRSA) and Pseudomonas Aeruginosa (PA) Compared to Comparator and Control Groups
SARASOTA, Fla., Dec. 8, 2023 — Omeza®, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, today presented in vivo data showing that OCM™ alone significantly reduced …
New Clinical Data Demonstrate >90 Percent Area Reduction in Diabetic Foot Ulcers within 12 Weeks or less Using Novel Omeza® Platform plus Offloading
SARASOTA, Fla., Dec. 6, 2023 — Omeza®, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, today announced interim clinical trial results showing that Omeza® combination therapy …
Omeza Announces New Tranche of Funding and Upcoming Q3 Clinical Activities
SARASOTA, Fla., Sept. 27, 2023 — Omeza, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, today announced that it has completed a $6.5 million offering and …
